Ubiquinol significantly improves the health of patients with advanced heart failure / it is also absorbed at a much higher rate in these patients
Researchers at East Texas Medical Center and Trinity Mother Francis Hospital in Texas note that supplementation with traditional Coenzyme Q10 fails to raise the bodys level of Coenzyme Q10 to adequate levels even when the heart failure patient is supplemented with 900mg a day. These patients often have plasma total CoQ10 levels of less than 2.5 mcg/ml and have limited clinical improvement. It is postulated that the intestinal edema in these critically ill patients may impair CoQ10 absorption.
We identified seven patients with advanced CHF with an average ejection fraction of 22%. They all had sub-therapeutic plasma CoQ10 levels with mean level of 1.6 mcg/ml on an average dose of 450 mg of Ubiquinone (traditional CoQ10) daily. All of these patients were changed to an average of 580 mg/day of Ubiquinol with follow-up plasma CoQ10 levels, clinical status, and ejection fraction measurements determined by echocardiography. Mean plasma CoQ10 levels increased from 1.6 mcg/ml up to 6.5 mcg/ml when switched to Ubiquinol. Mean ejection fraction improved from 22% up to 39% and clinical improvement has been remarkable with NYHA class improving from a mean of IV to a mean of II.
Ubiquinol has dramatically improved absorption in patients with severe heart failure and the improvement in plasma CoQ10 levels is correlated with both clinical improvement and improvement in measurement of left ventricular function. The study is published in the journal Biofactors, 2008;32.